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Background: Chronic stable angina pectoris (CSAP) is a common cardiovascular condition that endangers a patient’s
life quality and longevity. As demonstrated in several clinical trials, acupuncture is attested to be effective for
CSAP. Current trials are not adequate enough to provide high-quality evidence for clinical decision making, as a
result of inadequate methodology design and small sample size. Notably, stark controversy toward acupoint
specificity also exists in the clinical acupuncture trials for CSAP. Therefore, we designed the present study as a
randomized controlled trial primarily to investigate the effectiveness of acupuncture in addition to routine care
among patients with CSAP. Meanwhile, we examined whether acupoint on the disease-affected meridian (DAM)
is superior to either acupoint on the non-affected meridian (NAM) or non-acupoint (NA), to further investigate
the meridian-based characteristics of acupoint specificity.
Methods/Design: This study was a multicenter, assessor and statistician blinded, randomized controlled trial in China.
In this study, 404 participants in sum will be randomly assigned to four groups through central randomization in a
1:1:1:1 ratio. The whole study period is 20 weeks including a 4-week baseline period, a 4-week treatment period and a
12-week follow-up. Participants in the DAM group receive acupuncture stimulation at acupoints on the disease-affected
meridian, and three different control groups will undergo acupuncture stimulation at the NAM, the non-acupoint and
no intervention respectively, in addition to basic treatment. Participants in the acupuncture groups will receive 12
sessions of acupuncture treatment over 4 weeks, while the wait-listed (WL) group would receive free acupuncture
treatment after the completion of the study. The outcome measures in this trial include the frequency of angina
attack during 4 weeks as the primary outcome and eight other secondary outcomes.
Discussion: This trial will provide new and relatively high-quality evidence in acupuncture treatment for CSAP.
Moreover, this trial may further validate the meridian-based characteristics of acupoint specificity by comparing the
strength of acupoints on the disease-affected meridian versus that of the non-affected meridian, to further inspire
optimization of acupuncture therapy for CSAP.
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Chronic stable angina pectoris (CSAP) is a common
cardiovascular condition that endangers a patient’s life
quality and longevity, which is characterized by severe
chest pain and discomfort in the left anterior chest or
adjacent areas caused by myocardial ischemia [1]. Stable
angina affects more than 7.8 million people in the United
States, with an annual incidence of over 500,000 new cases
[2]. Despite the declining incidence of myocardial infarc-
tion, the prevalence of angina remains high, and direct
costs in the United States in 2000 have been estimated
at up to $75 billion [3]. As for China, the prevalence of
angina is 2.4% among males and 3.2% among females
[4], which makes it a serious social problem, considering
its large population base. In China, a large majority of
CSAP patients resort to acupuncture and other traditional
Chinese medicine (TCM) therapies in addition to conven-
tional drugs for treatment and recurrence prevention
[5,6], though discrepancies still exist concerning the effect-
iveness and efficacy of acupuncture therapy for angina.
Acupuncture, well known as an oriental healing tech-
nique that originated from ancient China, has been used
as a treatment method in Asia for over 2,000 years. Now-
adays, the therapeutic effect of acupuncture is gradually
being recognized in the western world. The National
Institutes of Health (NIH) Consensus has recommended
acupuncture as an alternative and complementary treat-
ment for many health conditions [7]. As demonstrated in
several international clinical trials 20 years ago, acupunc-
ture is effective for CSAP [8] in reducing disease duration
[9], anginal attack and nitroglycerin consumption [10], as
well as for improving cardiac work capacity [11]. Similarly,
clinical trials [12,13] and case observations [14-17] from
China in recent decades, accompanied with TCM experts’
opinions [18], have consistently confirmed that CSAP
patients may benefits from traditional acupuncture therapy.
Importantly, large amount of animal experiments have
already validated the myocardial protective effect of acu-
puncture for cardiac ischemia [19,20] and reperfusion via
inhibition of the beta(1)-adrenoceptor signaling pathway
[21,22] and regulation of myocardial enzyme level [23,24].
However, these Chinese clinical trials or observations and
international randomized controlled trials (RCTs) are not
adequate enough to act as high-quality evidence for clinical
decision making, as a result of inadequate methodology
design and small sample size [25]. Therefore, clinical trials
with sufficient sample size and sound methodology design
are necessary and meaningful to clinical practice.
Notably, there is a remarkable paradox in the afore-
mentioned international clinical trials validating the
effectiveness of acupuncture for CSAP, which is the
specificity of real acupoint when compared with sham
acupoint [8-11]. In TCM theory, multifaceted factors
contribute to therapeutic effect of acupuncture [26],among which, the selection of optimal acupoint is vital.
As to acupoint selection, the traditional acupuncture
theory emphasizes the indications and property of differ-
ent acupoints, which is known as acupoint specificity [27].
Acupoint specificity has been widely acknowledged and
considerably utilized as the basic law of traditional acu-
puncture practice. To elaborate, acupuncturists would
always prefer to choose acupoints on the disease-affected
meridian(s) for preferable treatment effect based on TCM
patterns resulting from syndrome differentiation [28].
Nevertheless, many reviews, meta-analyses and clinical
trials have merely demonstrated a statistical difference,
but not clinical significance between real acupoint and
sham point for various diseases [29-36]. These studies
have drawn the attention of many researchers and further
aroused controversy regarding the existence of acupoint
specificity. In 2010, the American Association of Acu-
puncture came to a consensus agreement and announced
in a white paper that acupoint specificity was one of these
two main paradoxes of forthcoming acupuncture research
[28]. Hence, clinical trials assessing the meridian-involved
acupuncture specificity is of great significance for guiding
clinical practice as well as for inspiring basic research
in acupuncture.
Therefore, we designed the present study as a random-
ized controlled trial to primarily investigate the effective-
ness of acupuncture, in addition to routine care, among
patients with CSAP. Meanwhile, we examined whether
acupoint on the disease-affected meridian (DAM) is su-
perior to either acupoint on the non-affected meridian
(NAM) or non-acupoint (NA), to further investigate the
meridian-based characteristics of acupoint specificity. The
present study was financially supported by the National
Basic Research Program (973 Program) in China and the
trial was registered with an identifier (NCT01686230) in
Clinical Trials.gov.
Methods/Design
Ethics review and informed consent
The study protocol was reviewed and approved by the
IRB of the Teaching Hospital of Chengdu University of
Traditional Chinese Medicine (No.2012KL-005). The
design of this trial is in accordance with the Declaration of
Helsinki (Version Edinburgh 2000). Before randomization,
all eligible patients will be informed of the details of the
study and all the benefits and risk that they may take from
this trial. Particularly, participants will be clearly told
about the equal chance of allocation to any one of the four
groups before signing the informed consent. Meanwhile,
they will be given enough time to decide whether they
join in the trial or not. Lastly, participants will be included
voluntarily by signing the written informed consent.
However, due to the principle of blinding, only patients
allocated to WL group will be told to wait for free
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information will be strictly restrained to patients in the
other three groups.
Design
This study was a multicenter, assessor and statistician
blinded, randomized controlled trial in China. In this study,
404 participants in sum would be randomly assigned to the
four groups through central randomization in a 1:1:1:1 ratio
(Figure 1, Table 1). Eligible participants will be recruited
from outpatient clinics and inpatient departments of Cardi-
ology in the following five clinical centers in different
regions of China: Chengdu University of TCM, Hunan
University of TCM, Yunnan College of TCM, Guiyang
College of TCM and Shanxi College of TCM.
Randomization
The central randomization is performed by the Company
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Figure 1 Trial flow chart.System (CIMS). Allocation to the treatment groups
uses a stratified block dynamic randomization method
with permuted block, which is automatically under the
control of a central computer system. The website and
mobile messages will be used to send randomization
information (including the participants’ name in pinyin
format, gender and date of birth) to the center. To
guarantee allocation concealment, randomization will
be done by an independent researcher. An independent
assessor will interview the participants and perform the
screening. Random numbers and group assignment will
be confirmed through email or short message service
(SMS) to the independent assessor immediately. This
procedure guarantees that randomization concealment is
adequate, and not influenced either by the acupuncturists
or by the participants. Participants allocated to groups will
be blinded to their treatment allocation; however blinding
is clearly not possible in the WL control group. We shall




















Table 1 Trial process chart
Period Baseline Inclusion Treatment Follow-
up
Measurement 1 2 3 4 5










× × × × × ×
Physical examination ×
Outcomes
Angina diary × × × × × ×
The frequency of
angina attack
× × × × × ×
The dosage of
nitroglycerin
× × × × × ×
Angina pectoris grade × × × × ×
The pain severity
of angina(VAS)
× × × × × ×
SAQ score × × × × ×
Six minutes’ walk test × ×
SAS and SDS × × × ×
24 hours dynamic ECG × ×
Cardiovascular events × × × ×
Trial evaluation






ECG, dynamic electrocardiograph; SAQ, Seattle Angina Questionnaire; SAS,
Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; VAS, Visual
Analogue Scale.
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that all the treatments provided are effective. All partic-
ipants will be assessed and the results analyzed by pro-
fessionals blinded with respect to the allocations of the
different treatments.Participants
Study population
This trial focused on the patients with CSAP. Eligible
patients should match the inclusion criteria; ineligible
patient should be excluded according to the exclusion
criteria.Inclusion criteria
Participants will be included if they fulfill the following
criteria:1) patients meet the diagnostic criteria of ACC/
AHA angina pectoris of coronary heart disease [37]; 2)
35 ≤ age ≤80 years, male or female; 3) the onset of angina
pectoris ≥3 months previous and the frequency of angina
attack ≥ twice a week; and 4) patients signed the informed
consent.
Exclusion criteria
Patients with any of the following conditions will be
excluded: 1) age ≤35 or age ≥80; 2) pregnant or lactating
women; 3) have complicated cardiovascular, digestive,
respiratory, urinary, blood, nervous, endocrine system
and other severe primary diseases and failed to effectively
control in clinic; 4) have psychiatric, allergic or blood
disorders; 5) have acute coronary syndrome (including
acute myocardial infarction and unstable angina), severe
arrhythmias (severe atrioventricular block, ventricular
tachycardia, heartbeat influencing the flow dynamics in
supraventricular tachycardia, frequent heartbeat and
premature beat and especially premature ventricular
contractions), atrial fibrillation, primary cardiomyopathy
and valvular heart disease; 6) uncontrolled or mismanaged
blood pressure and blood glucose; 7) cardiovascular
disease that had been treated with acupuncture within
recent three months; or 8) undergoing other clinical
trials.
Recruitment procedures
The following scheme will be used to recruit participants
with angina pectoris. Patients visiting the outpatient
clinics and inpatient department in every clinical center
will be informed by the cardiologist of the present trial.
Research assistants will continue the enrollment process
by screening eligible participants according to the inclu-
sion/exclusion criteria. Potential patients in local com-
munities and out-hospital clinics will be recruited by
advertisements in the post, leaflets, TV broadcast and
newspapers. Participants will be included only if they
meet the inclusion criteria and provide written informed
consent indicating that they agree to every procedure of
the trial and join in the trial willingly.
Interventions
In order to ensure the safety of participants, fulfill ethic
necessities and improve the prognosis of patients with
angina pectoris, we adhered to the European and Chinese
Guidelines for the management of patients with chronic
stable angina recommendation [37,38]. All participants
in the four groups will receive same basic treatment. In
addition, according to the guidelines and clinical condi-
tions in China, we shall prescribe antianginal drugs for
patients suffering acute angina attack.
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from the clinical practice of TCM. The final scheme
was discussed and revised according to advice of clinical
acupuncture experts who were consulted in China. Partici-
pants in the acupuncture groups will receive 12 sessions
of acupuncture treatment over 4 weeks. In each session,
participants in all groups except for WL will receive
acupuncture treatment bilaterally three times per week
and each session will last for 30 min. Each group shares
the same basic treatment including health education
and basic drug therapy. The whole study period is 20
weeks including a 4-week baseline period, a 4-week
treatment period and a 12-week follow-up. We required
each participant to record the details of each angina attack
and remission in angina diaries. The angina diaries should
be kept from baseline to 12 weeks after randomization.
All outcomes will be assessed at baseline period and in
the 4th, 8th, 12th and 16th weeks after randomization,
according to the diaries and related checks.
Basic treatment
Basic treatment includes health education and primary
drugs. We recommend lifestyle modification including
increasing exercise, limiting alcohol consumption, weight
loss, quitting smoking, etcetera for all patients in health
education. Basic medication includes aspirin (100 mg once
a day); metoprolol (25 mg twice a day); ramipril (5 mg
once a day); and atorvastatin (20 mg once every night)
[37,38]. Basic treatment lasted from baseline to the com-
pletion of the follow-up period.
Antianginal therapy
Antianginal therapy includes nitroglycerin, nifedipine tab-
lets and suxiao jiuxin wan [39]. In emergency cases of
angina attack, participants will be instructed to administer
one kind of medicine according to previous treatment
history and personal contraindication. Basically, for all
patients, we recommend nitroglycerin. Regardless of the
type of medicine, participants are required to carefully
record the details of medicine, including name, adminis-
tration time and dosage. Researchers will provide these
three drugs to standardize the basic treatment for free:
Nitroglycerin (Beijing Yimin Pharmaceutical Co., Ltd.,
Beijing, China) with State Food and Drugs Administra-
tion (SFDA) (China) registration number (H11021022),
sublingual dose of 0.5 mg (one tablet); Nifedipine Tablets
(CSPC Pharmaceutical Group Limited, Shijiazhuang,
China, SFDA: H13021315), oral dose of 10 mg (one
tablet); Suxiao Jiuxin pills (SX) (Zhongxin Pharma
Tianjin No. 6 Traditional Chinese Medicine Factory,
Tianjin, China, SFDA: Z12020025), sublingual dose of 5
to 10 pills. Other antianginal drugs would be consid-
ered to violate the study protocol, for which the patient
would be eliminated.There will be one treatment group receiving acupuncture
stimulation at acupoints on the disease-affected meridian
(DAM), and three different control groups undergoing
acupuncture stimulation at acupoints on a non-affected
meridian (NAM), non-acupoints (NA) and no interven-
tion, respectively, in addition to routine care. The location
and needling methods for acupoints and non-acupoints are
demonstrated in Table 2. The name/code and location of
the acupoints are consistent with the WHO standards [40].
DAM group
Based on TCM theory, angina pectoris commonly affects
the heart and pericardium meridian, and acupoints located
on these two meridians are essential components of
acupoint prescription for heart diseases in acupuncture
clinics. Thus, we selected Neiguan (PC6) and Tongli
(HT5) as obligatory acupoints. PC6 has profoundly been
regarded as the key acupoint for curing heart and chest
disease in Chinese medicine. As clinically indicated,
PC6 can improve cardiac function, enhance myocardial
contractility, increase coronary artery blood flow and
myocardial oxygen supply and relieve angina pectoris
[16,41,42]. HT5 functions to calm the spirit and regulate
heart rhythm. The combination of HT5 and PC6 are
frequently used to treat angina pectoris and arrhythmia
clinically [15].
NAM group
In this group, we selected Taiyuan (LU9) and Kongzui
(LU6), both of which belong to Lung Meridian of Hand
Taiyin. This meridian and its related acupoints in clinical
acupuncture practice are not the preferred choice for
treating angina pectoris [43]. Nevertheless, they are
located inside the forearm, which makes it a suitable
control because acupoints chosen in the DAM group
are located in the same body area.
NA group
We will provide non-acupoint acupuncture treatment
for patients in the NA group, in which pre-validated
sham acupoints [44] and real insertion of acupuncture
needles at bilateral non-acupoints will be administrated,
but without achieving a ‘deqi’ sensation.
WL group
Participants in this group will receive no acupuncture-
related intervention while the trial is in process, but will
receive a free 12-session acupuncture treatment over 4
weeks after the completion of the study.
The doctors performing all treatment procedures have
at least 5-year experience of acupuncture treatment and
a TCM license. All acupoints will be punctured with
disposable stainless steel needles (0.25 mm × 40 mm;
0.25 mm × 25 mm; Suzhou Huatuo Medical Appliance
Table 2 Details of each group
Group Interventions Acupoints Manipulation
Acupoint on disease- affected meridian Acupuncture and
basic treatment
Neiguan (PC6) Both points are punctured bilaterally
and perpendicularly 2 to 4 cm
Tongli (HT5)
Acupoint on non-affected meridian Acupuncture and
basic treatment
Taiyuan (LU9) Both points are punctured bilaterally
and perpendicularly 2 to 4 cm.
Kongzui (LU6)
1) On the front arm of deltoid muscle
and biceps brachi junction.
Non-acupoint Acupuncture and
basic treatment
2) On the ulnar side of the arm, half way
between the epicondylus medialis of the
humerus and the ulnar side of the wrist.
Both points are punctured bilaterally
and perpendicularly 3 to 5 cm.
Waiting list Basic treatment
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nipulated in a lifting and thrusting technique combined
with twirling and rotating manner until the patient
feels numbness or other acupuncture sensation (known
as ‘deqi’). Then, an auxiliary needle (0.18 mm × 13 mm)
will be inserted to 2 mm away from the acupuncture
needle to a depth of 2 mm. No manipulation will be
delivered to the auxiliary needle. Acupuncture needles
and auxiliary needles will be separately connected to an
electrode-powered by HANS-200A stimulator (Nanjing
Jisheng Medical Technology Company, Nanjing city,
China), to induce stimulation to further activate acupoint
for 30 min with 2 Hz, rarefaction wave. The electrical
stimulation intensity will be adjusted from 0.1 mA to 2.0
mA to make the patients feel comfortable. After retaining
for 30 min, all needles will be withdrawn with clean cotton
balls pressed to the skin to prevent bleeding.
Outcome measurement
The primary outcome in this trial is the change from
baseline in frequency of angina attack at 4 months. The
primary endpoint will be measured 1 day before the
inclusion, and the 1st day of the 4th, 8th, 12th and 16th
weeks after inclusion.
The secondary outcomes include the following eight
items: 1) pain severity of angina (VAS Score); 2) reduction
of the dosage of nitroglycerin or Suxiao Jiuxin wan; 3)
improvement of exercise capacity assessed by Six minutes’
walk test; 4) changes of ST-T in dynamic ECG; 5) score of
Seattle Angina Questionnaire (SAQ); 6) self-rating anxiety
scale (SAS); 7) self-rating depression scale (SDS); and 8)
incidence of cardiovascular event during the 4 months
(developing into unstable angina, acute myocardial infarc-
tion and even death).
The six minutes’ walk test and dynamic ECG will be
simultaneously measured 1 day before and in the 4th
week after inclusion. Others endpoints are measured 1
day before and in the 4th, 8th, 12th and 16th weeks after
inclusion.Practitioners Training and quality control
All researchers involved in this trial, all clinical physicians
who enroll participants and all assessors who collect data
must attend training classes to make sure all practices at
each hospital are generalized and standardized. There are
both theoretical and practical courses in the training clas-
ses. All practitioners finishing the training courses will be
accredited a trial certificate by passing the examination.
In order to guarantee the quality of trial process, quality
monitoring will be carried out by the CIMS every 3
months, and specially trained physicians will inspect and
document the details of the entire trial process.
Safety and adverse event
For the sake of patient safety, prevention measures and
emergency medical plans will include well-equipped treat-
ment rooms, emergency department, cardiovascular spe-
cialist and first-line clinical physicians. All adverse events
(AEs) associated with acupuncture would be recorded
during the treatment and the follow-ups; these AEs
include bleeding, hematoma, fainting, serious pain, local
infection, etcetera. On the other hand, AEs commonly
associated with the anti-anginal drugs (basic therapy)
will be documented as well, (for example, headaches,
dizziness, nausea, flushing, abdominal pain, etcetera) [45].
Serious adverse events (SAE) are defined as death or life-
threatening events, which may require inpatient hospi-
talization, cause prolongation of existing hospitalization,
or even result in persistent or significant disability/incap-
acity and need intervention to prevent permanent im-
pairment or damage. If participants suffer any AE/SAE,
all details will be documented and reported. Further-
more, SAE will be reported to the principal investigator
and the ethics committee immediately so that they can
make a decision on whether the patient should withdraw
from the trial.
Sample size calculation and statistical analysis
The sample size calculation was based on a previously
study by Richter A. et al. [8]. According to which, the
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In this study, we incorporated the early clinical pretest,
the difference of clinical effect for frequency of weekly
angina attacks (DAM and NA) was estimated to be 4.2.
Standard deviation for each of the four groups was 8.5
times (α = 0.05; 1-β = 0.90). According to the estimation
with NQuery Advisor (Version 4.0, Statistical Solutions
Ltd, Ireland), in the bilateral testing, 352 cases are required
in this study with 88 cases for each group.
Considering a 15% dropout, therefore, 404 participants
in sum should be included in this trial with 101 for each
group.
Statistical analysis will be performed by a statistician
blinded to the whole trial process using SAS (Version
9.1, SAS Institute Inc, USA) statistical Software packages
in the CIMS. For the evaluation of curative effect in this
trial, the per-protocol set (PPS) was used. The full analysis
set (FAS) was determined according to intention-to-treat
population (ITT) and all the patients who were random-
ized and received at least one treatment session were
included in the analysis set. The per-protocol (PPS)
population was defined as the patients who completed
the study and did not have major protocol violations.
Demographic data and other basic indicators were ana-
lyzed to measure the balance of the four groups in the
baseline. The main indicators and global indicators
were analyzed with FAS and PPS. We described the
results with the mean, standard deviation, median, P25,
P75, maximum and minimum values of the differences
between the treatment period and the baseline period.
So that a multicenter clinical trial can be adopted in
the study, the central effect on the efficacy indicators
shall be considered in the analysis. During the comparison
of the various groups, other factors that might affect
the efficacy will be considered as co-variants for covari-
ance analysis or logistic regression analysis. Missing data
will be replaced according to the principle of multiple
imputation.
Discussion
This study potentially may confirm that acupuncture is
effective for CSAP in addition to routine care. Our study
may further confirm meridian-based acupoint specificity.
In the present study, we establish one treatment group
and three control groups in this randomized controlled
trial. Over the past 20 years, strategies for clinical acu-
puncture controls fall under three categories: 1) sham
acupuncture, in which the skin is punctured with real
acupuncture needles either fully at non-acupoint locations
or shallowly at acupoint locations; 2) placebo acupuncture,
which utilizes non-penetrating acupuncture devices; and
3) wait list and ‘treatment as usual’ [46]. In this study
we have adopted both sham acupuncture and wait list
controls. Our aim for establishing those two groups isto differentiate and isolate the placebo effect and patient
expectancy [47,48] in particular, to further validate the
pure effect of acupuncture.
Moreover, the reason we chose acupoints on the Lung
meridian in the NAM group as a control to the treatment
group is that 1) previous studies have paid close attention
to comparisons of the power of real-acupoint with sham-
acupoint, however no clinical trials in CSAP have focused
on the comparison between acupoints on different merid-
ians; 2) Lung meridian acupoints selected in the NAM
group of this trial are located at the upper anterior
extremity the superficial acupoint shares the same
anatomical tissue as the brachial plexus nerve acupoints
of the DAM group. It is hypothesized that by this man-
ner, the effect of NAM could control that of DAM; 3)
acupoints on the lung meridian, according to trad-
itional acupuncture theory, are not closely related and
are not frequently prescribed for heart diseases, which
made it a sub-optimal choice for CSAP. Thus, selecting
the acupoints on heart meridian which is believed to be
most closely related and indispensable to heart disorders
[43], compared with the Lung meridian, is extremely
meaningful and helpful in optimizing acupuncture pre-
scription for CSAP.
In conclusion, this trial will provide new and relatively
high quality evidence in acupuncture treatment for CSAP.
Moreover, this trial may further validate the meridian-
based characteristics of acupoint specificity by comparing
the strength of acupoints on disease-the affected meridian
versus that of a non-affected meridian, to further inspire
optimization of acupuncture therapy for CSAP.
Trial status
The trial is currently recruiting patients.
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